ANX-042 / Mayo Clinic, Anexon - LARVOL DELTA

Dose-Dependent Dissociation of Renal and Systemic Effects of ANX-042 in HFrEF: A Phase 1b Crossover Study (AHA 2026) - "Abstract is embargoed at this time."

P1 data • Cardiovascular

Beyond biomarkers: designer natriuretic peptides and cGMP centered therapies for cardiorenal and cardiometabolic protection in chronic heart failure. (PubMed, Intern Emerg Med) - "Recent advances in peptide engineering have enabled the development of novel designer NPs, including Cenderitide, aimed at restoring and enhancing their signalling...Additional engineered peptides, including ANX042, MANP, and CRRL269, as well as complementary approaches targeting the cGMP pathway, such as soluble guanylate cyclase (sGC) stimulators, neprilysin inhibitors, and GC-A positive allosteric modulators, are further expanding the therapeutic potential of NP-centred therapies. Beyond cardiovascular effects, NPs also influence metabolic regulation and renal function, highlighting their relevance in cardiometabolic disease. Collectively, these developments support a shift from the use of NPs solely as biomarkers toward their emerging role as therapeutic targets and agents in the treatment of CHF."

Biomarker • Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders

ANX-042 Aim 1: Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Mayo Clinic | Enrolling by invitation ➔ Completed | N=60 ➔ 40

Enrollment change • Trial completion • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension • Nephrology • Renal Disease

ANX-042 Aim 1: Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome (clinicaltrials.gov) - P1 | N=60 | Enrolling by invitation | Sponsor: Mayo Clinic | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension • Nephrology • Renal Disease

ANX-042 Aim 1: Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome (clinicaltrials.gov) - P1 | N=60 | Enrolling by invitation | Sponsor: Mayo Clinic | Trial completion date: Sep 2023 ➔ Dec 2023 | Trial primary completion date: Jul 2023 ➔ Dec 2023

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension • Nephrology • Renal Disease